Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 14/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.46 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9544995 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL192535 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL29015574 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL252870 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL192536 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL23452261 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL7462140 | 0.90 | MCL1 (0.53) | MCL1P2RX3 | |
| SCHEMBL27190373 | 0.90 | MCL1 (0.53) | MCL1P2RX3 | |
| SCHEMBL27190288 | 0.90 | MCL1 (0.53) | MCL1P2RX3 | |
| SCHEMBL7722150 | 0.90 | MCL1 (0.50) | MCL1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770741-B1 | USEFUL IN TREATING CONDITIONS AND DISEASES OF A MAMMAL AND HUMAN IN WHICH AN EXCESS OF BRADYKININ OR RELATED KININS ARE PRODUCED OR INJECTED SUCH AS BY INSECT BITES | SCIOS INC. | 2004-08-03 | — | — | US | disclosed |
| EP-0618810-B1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
| US-5385889-A | Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist | SCIOS NOVA INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0618810-A4 | BRADYKININ ANTAGONIST PEPTIDES. | SCIOS NOVA INC (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0618810-A1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |